Back in February, roughly 7 months ago, I recommended Unity to paying subscribers.This was a tough pick to make. In the weeks ahead, the market would have to deal with the onslaught of Liberation ...
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...
UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results